{ "schemaVersion": "deck-intelligence.v1", "id": "019de073-3cb6-7521-8cc2-fe64231d84c9", "slug": "d538949ee3add2afed287b359e626655", "title": "AN2 Therapeutics | Investor Presentation Deck | 25 slides", "subtitle": "AN2 Therapeutics · 2022-08", "author": "AN2 Therapeutics", "date": "2022-08-01 00:00:00", "pageCount": 25, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de073-3cb6-7521-8cc2-fe64231d84c9", "slug": "d538949ee3add2afed287b359e626655", "title": "AN2 Therapeutics | Investor Presentation Deck | 25 slides", "rawTitle": "AN2 Therapeutics | Investor Presentation Deck | 25 slides", "authorId": "an2-therapeutics", "authorName": "AN2 Therapeutics", "authorDisplay": "AN2 Therapeutics", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2022-08__an2-therapeutics__investor-pres__d538949e.pdf", "sourceUrl": "https://www.slidebook.io/company/an2-therapeutics/presentation/d538949ee3add2afed287b359e626655/", "sourceDate": null, "presentationDate": "2022-08-01 00:00:00", "ingestedAt": "2026-04-30 22:12:21.916915+00", "status": "ready", "pageCount": 25, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2022-08__an2-therapeutics__investor-pres__d538949e", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Investor Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 25, "pagesIndexed": 25, "pagesWithImages": 25, "pagesWithMetadata": 25, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 127, "chartCount": 9, "metricSlides": 0, "toolMatches": 9, "documentToolMatches": 0, "frameworkMatches": 6, "arcMatches": 1, "beatMatches": 4, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "evidence": "The deck follows a structure similar to the Sequoia Pitch, with a clear problem statement, market sizing, solution overview, traction, and financial/IPO plans", "isPrimary": true, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:24:39.407964+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 8, "name": "Problem", "beatId": "3c9832b8-bfc2-4ca8-ad8d-8f1231fddb47", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slides 8-10 present the problem statement, market sizing, and current treatment regimens", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.9 }, { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 12, "name": "Solution", "beatId": "fbdd29f4-3b4e-4837-b922-52ede9c2a8ae", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 12-14 present the solution overview, including epetraborole's novel mechanism of action and broad antimicrobial activity", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.9 }, { "to": 17, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 14, "name": "Traction", "beatId": "679127e2-5c80-423c-8aa7-8057beadd113", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": null, "evidence": "Slides 14-17 present traction, including Epetraborole's improved antibacterial activity and favorable pharmacokinetics", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.9 }, { "to": 22, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 19, "name": "Business Model", "beatId": "397f2f22-31e1-4ec6-8a66-a5d5f79bbcd3", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": { "name": "Business Model", "slug": "sequoia-pitch-business-model", "status": "active", "canonId": "019dd9b8-22f4-768a-8822-31509f575122", "version": 1, "description": null }, "evidence": "Slides 19-22 present the business model, including market opportunity, target product profile, and intellectual property", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 10, "from": 8, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "13b74b4b-a68a-4f96-aedb-d9fa2b458a5f", "evidence": "The problem statement and market sizing slides imply the cost of inaction", "position": 0, "objective": "What is the cost of not addressing NTM lung disease?", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:24:39.618722+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 14, "from": 12, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null, "categoryName": "Vision", "categorySlug": "vision" }, "matchId": "88233dcc-135b-430e-bef3-14bb541736d0", "evidence": "The solution overview slides present the why, what, and how of epetraborole", "position": 1, "objective": "Why is epetraborole a compelling solution?", "confidence": 0.8, "extraction": { "at": "2026-07-17 03:24:39.654225+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "d82710ae-0a8a-4394-a8e6-11314dfdc777", "evidence": "The slide presents a problem statement with several components, including a headline, paragraph, callout, and tables.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:35:26.656737+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "d2e3fb02-9b5a-4ffa-8f98-5e1a321198b3", "evidence": "The slide presents a table with data from the CONVERT study.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 03:35:26.740035+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "660fd7c9-fcd1-4f18-9657-0dbd4575d7ab", "evidence": "The slide presents a table comparing MIC values for Epetraborole, Clarithromycin, and Amikacin.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 03:35:26.861773+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Comparison frame", "slug": "comparison-frame", "status": "active", "bestFor": null, "canonId": "019dd9e1-484b-7399-a4fc-d14644b99f93", "version": 1, "bodyDocId": null, "description": "Two or more states/subjects placed side by side to expose a gap.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3b646261-1d64-442f-b3bc-cce41a534d4a", "evidence": "comparison_table", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:35:43.494542+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "69c3b563-3b32-41b3-8645-5818d9ea391d", "evidence": "source-note: 1. Wu ML, Aziz DB, Dartois V, Dick T. NTM drug discovery: status, gaps and the way forward. Drug Discov Today. 2018;23(8):1502-1519. 2. Spero Therapeutics. 3. Redhill Biopharma.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 03:35:43.576205+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4a060af3-898d-49bc-b20a-cd2a3c7d43ae", "evidence": "chart/timeline: Clinical trial timeline from 2021 to 2024", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:07:28.729471+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "9cf297fa-c309-4359-8a06-98b9cfe387b1", "evidence": "list/bullet: AN2 leadership team is committed to applying our know-how to help solve some of the toughest infections in global health.", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:07:28.799885+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "ef02a5bb-4f19-4287-bf58-a35155d31fc6", "evidence": "list/bullet: Phase 2/3 pivotal trial expected to support U.S. and Japan regulatory approval for treatment-refractory MAC lung disease; initiated study June 2022; topline Phase 2 data mid 2023; QIDP, Fast Track, and orpha", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:07:28.869446+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Audience Persona", "slug": "audience-persona", "status": "active", "bestFor": null, "canonId": "019dd956-7fe3-74e9-88b8-be0bea34f219", "version": 1, "bodyDocId": null, "description": "Detailed fictional profile of typical audience member including goals, frustrations, and context", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "fbe0f7d1-5b65-40ef-b799-9678955ca8ad", "evidence": "paragraph/paragraph: Developing treatments for rare, chronic, and serious infectious diseases with high unmet needs", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:07:28.940039+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "6b81a8c8-29b6-4e1b-964a-42fa17b7bf6e", "evidence": "The table visualizes project timelines across clinical phases.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:36:40.947+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "gantt-chart" }, { "matchId": "d8eb4d09-a740-4a36-a7f4-0b1b0a2916f8", "evidence": "Nested circles showing total addressable market down to specific indication", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:36:47.48+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "market-segmentation-pyramid" }, { "matchId": "058d9001-c49a-429b-9ebd-9a83bf29971b", "evidence": "Visual representation of clinical trial phases over time", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:36:42.878+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "frameworkName": "timeline" }, { "matchId": "63440f13-d587-4e09-bcad-117c2b654150", "evidence": "Funnel diagram used to segment NTM lung disease markets", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:36:43.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "frameworkName": "market-segmentation-pyramid" }, { "matchId": "b014cb5c-bd4a-4cbf-9c8e-a09154bd086d", "evidence": "Comparison of product features against competitors", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:36:42.647+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "frameworkName": "comparison_frame" }, { "matchId": "748ed387-ce5e-41d3-a4e9-9c1818b61eb8", "evidence": "The slide uses a horizontal timeline to map clinical milestones against calendar years.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:36:42.889+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "frameworkName": "timeline" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "title": "The slide uses a global map background and patient portraits to emphasize the scope and human impact of the company's mission.", "function": "inspire_vision", "imagePath": "https://imgproxy.kitesheet.com/mNmDiF8w1pqsYV9Wxo-Xd8lWWZg_7gYnLuvwfX-TUfk/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9kNTM4OTQ5ZWUzYWRkMmFmZWQyODdiMzU5ZTYyNjY1NS9wMDAxLmpwZw", "rawType": "mission", "block": null, "metadata": { "slideType": "mission", "slideTypeCanon": { "name": "Mission", "slug": "mission", "status": "active", "canonId": "019de52d-0fce-7496-b34c-18fd6a6e3310", "version": 1, "description": null }, "function": "inspire_vision", "functionCanon": { "name": "Inspire vision", "slug": "inspire_vision", "status": "active", "canonId": "019de52d-16d0-7756-83de-376eeac6fa40", "version": 1, "description": null }, "density": "balanced", "densityScore": 25, "componentCount": 4, "textChars": 154, "nDataPoints": 0, "notes": "The slide uses a global map background and patient portraits to emphasize the scope and human impact of the company's mission.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:41.553+00", "seconds": 4.798, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/1", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-1", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.85, "w": 0.55, "x": 0.4, "y": 0.08 }, "kind": "image", "text": "Group of patient portraits", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.553+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0f004d6e-6431-4824-bdeb-3f0fb1a12b16", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.38, "x": 0.03, "y": 0.32 }, "kind": "paragraph", "text": "Developing treatments for rare, chronic, and serious infectious diseases with high unmet needs", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.553+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "938fb9c5-1fa1-4a2a-8da0-a78b601e28fa", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.03, "y": 0.95 }, "kind": "paragraph", "text": "AN2THERAPEUTICS.COM", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.553+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a075b9f8-b29f-42d5-9725-0d6337db3d45", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.35, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "AN2Therapeutics", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.553+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ea3b31b1-63f3-4ec8-a52a-6cfcd2c59c21", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/B2GVixTYiD0DSc88dfJnx5_ShfnSf9MvVQyEkIM2NAI/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9kNTM4OTQ5ZWUzYWRkMmFmZWQyODdiMzU5ZTYyNjY1NS9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/VivihIrQKtJlAlztEdt5t9gv8LPeClcCeI_hFNcZ2zM/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9kNTM4OTQ5ZWUzYWRkMmFmZWQyODdiMzU5ZTYyNjY1NS9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/hnDeLq9UDzooXybG435eN2MizeOL1OjqEQst8e9kSh0/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9kNTM4OTQ5ZWUzYWRkMmFmZWQyODdiMzU5ZTYyNjY1NS9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 8, "componentCount": 2, "textChars": 98, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:39.931+00", "seconds": 2.414, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/2", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-2", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.9, "w": 0.7, "x": 0.27, "y": 0.02 }, "kind": "disclaimer", "text": "FORWARD-LOOKING STATEMENTS... FINANCIAL INFORMATION; USE OF PROJECTIONS... TRADEMARKS...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:39.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c5bd429e-c5d0-4261-a53a-51c8a4d40244", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.05, "y": 0.07 }, "kind": "title", "text": "Disclaimer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:39.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "adc4d4a9-7957-49ef-af51-abff80be7198", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "setup", "function": "front_matter", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 11, "componentCount": 3, "textChars": 59, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:39.821+00", "seconds": 2.188, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/3", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-3", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 1, "w": 1, "x": 0, "y": 0 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:39.821+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e63fcd9e-66c1-4b63-a865-1e34a4361eae", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.45, "x": 0.03, "y": 0.52 }, "kind": "paragraph", "text": "Eric Easom\nCo-Founder, President, and CEO", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:39.821+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "487cb3c9-448e-443c-a780-476eb6c4e441", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.03, "y": 0.37 }, "kind": "title", "text": "Corporate Overview", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:39.821+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bd481014-77b6-4f63-a117-b50573b49e03", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 4, "type": "setup", "title": "The slide uses a grid layout to display headshots, names, titles, and company logos for both management and board members.", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 24, "componentCount": 4, "textChars": 140, "nDataPoints": 0, "notes": "The slide uses a grid layout to display headshots, names, titles, and company logos for both management and board members.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:40.898+00", "seconds": 3.22, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/4", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-4", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.65, "x": 0.29, "y": 0.12 }, "kind": "image", "text": "Headshots of management and board members", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:40.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6deed4eb-3d9d-44a7-aa84-835b49e5c29a", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.15, "x": 0.29, "y": 0.07 }, "kind": "title", "text": "SENIOR MANAGEMENT", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:40.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "126c0d17-64dd-4dcc-aa9f-480e27212797", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.22, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "Team with significant experience in bringing medicines to market", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:40.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2f5aa477-3df6-4d5b-b74f-dec788ddae5d", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.15, "x": 0.29, "y": 0.415 }, "kind": "title", "text": "BOARD OF DIRECTORS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:40.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4bece995-84cc-4b24-b94e-7fe73b080da8", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 5, "type": "setup", "title": "The slide uses a split-layout with company mission on the left and product details on the right.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 86, "componentCount": 8, "textChars": 1293, "nDataPoints": 3, "notes": "The slide uses a split-layout with company mission on the left and product details on the right.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:41.845+00", "seconds": 4.157, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/5", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-5", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.65, "x": 0.3, "y": 0.82 }, "kind": "callout", "text": "We expect our boron chemistry expertise to drive future pipeline of differentiated compounds", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.845+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "06122da7-2bdf-477a-8335-637dd21de042", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.65, "x": 0.3, "y": 0.1 }, "kind": "list", "text": "Epetraborole (EBO): Pivotal phase 2/3 ready antibiotic product candidate for non-tuberculous mycobacterial (NTM) lung disease", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.845+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6f293b2d-5542-4097-8847-21ea3222bb2f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.65, "x": 0.3, "y": 0.75 }, "kind": "list", "text": "Potential to develop epetraborole to address additional geographies and NTM indications", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.845+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "779cce92-06d8-4a98-93e8-81e2fe0c4c23", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.65, "x": 0.3, "y": 0.2 }, "kind": "list", "text": "Large market opportunity given the high unmet need; Arikayce, the only approved therapy for NTM lung disease, had 2021 WW net sales of >$189M in its third year on the market (Arikayce 2Q'22: WW $65.2M +44% Y/Y)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.845+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9e067aba-4071-4a98-8b02-eb45a0db13b4", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.65, "x": 0.3, "y": 0.6 }, "kind": "list", "text": "Phase 2/3 pivotal trial expected to support U.S. and Japan regulatory approval for treatment-refractory MAC lung disease; initiated study June 2022; topline Phase 2 data mid 2023; QIDP, Fast Track, and orphan drug designations granted in U.S.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.845+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c84898c9-8d03-4614-ab69-bb56c91b21a4", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.65, "x": 0.3, "y": 0.35 }, "kind": "list", "text": "Ideal Target Product Profile: Novel mechanism of action, broad spectrum antimycobacterial activity; Convenient, once-daily oral dosing; Superior profile compared to SoC combination regimen in preclinical NTM models; Multiple Phase 1 studies out to 28 days of dosing support well-tolerated dose and high probability of target attainment", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.845+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ea34f056-2231-41cb-99de-7c0ef4de2897", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.25, "x": 0.05, "y": 0.1 }, "kind": "paragraph", "text": "AN2 Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.845+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "54893bff-cd5a-45c8-b131-911a271a8a65", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.3, "y": 0.93 }, "kind": "source-note", "text": "1. Insmed FY 2021 10-K 2. Insmed 2Q 2022 10-Q", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.845+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "86a81d83-7352-4ec1-807b-420c1dd22df8", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 6, "type": "resolution", "title": "The slide uses a Gantt-style visualization for clinical trial progress.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 32, "componentCount": 4, "textChars": 274, "nDataPoints": 0, "notes": "The slide uses a Gantt-style visualization for clinical trial progress.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:40.947+00", "seconds": 2.973, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/6", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-6", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.16, "x": 0.42, "y": 0.27 }, "kind": "chart", "text": "Clinical trial progress bars", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:40.947+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "395b65e3-2a0c-4d00-bb28-80095862b649", "parentComponentId": null }, { "bbox": { "h": 0.82, "w": 0.71, "x": 0.27, "y": 0.07 }, "kind": "table", "text": "Pipeline table with columns: Epetraborole, Preclinical, Phase 1, Phase 2/3, Next Steps, Rights", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:40.947+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "95b265e5-4306-40a9-99a5-39af89872ff9", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.24, "x": 0.04, "y": 0.31 }, "kind": "title", "text": "Boron chemistry approach enables targeting of novel biological targets", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:40.947+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "644e38ce-85db-468b-b73c-5a56ec374b5e", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.24, "x": 0.04, "y": 0.07 }, "kind": "title", "text": "Pipeline targets high unmet needs in rare, chronic and serious infectious diseases", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:40.947+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6f6d5079-5acc-41e4-bd38-bcb981cebeae", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "6b81a8c8-29b6-4e1b-964a-42fa17b7bf6e", "evidence": "The table visualizes project timelines across clinical phases.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:36:40.947+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 7, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 4, "componentCount": 2, "textChars": 30, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:40.187+00", "seconds": 2.203, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/7", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-7", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 1, "w": 0.6, "x": 0.4, "y": 0 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:40.187+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fb1dd216-12c5-47f2-a6ef-6d3a859640b8", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.05, "y": 0.42 }, "kind": "title", "text": "Epetraborole: NTM Lung Disease", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:40.187+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2823efe0-f35f-4944-b854-824d9ea66f35", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 8, "type": "tension", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "dense", "densityScore": 52, "componentCount": 3, "textChars": 1285, "nDataPoints": 3, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:40.901+00", "seconds": 2.895, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/8", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-8", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.68, "x": 0.28, "y": 0.84 }, "kind": "disclaimer", "text": "1. Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015;36(1):13-34; www.bacterio.net/mycobacterium.\n2. Nontuberculous Mycobacteria (NTM) Infections, Healthcare-Associated Infections, Centers for Disease Control webpage (last updated August 12, 2019).\n3. Nontuberculous Mycobacteria Lung Disease, Rare Disease Database, National Organization for Rare Disorders webpage (last updated 2018).\n4. Who Is At Risk? About NTM Fact Page, Insmed webpage.\n5. Diel R, et al. High mortality in patients with Mycobacterium avium complex lung disease: a systematic review. BMC Infect Dis. 2018;18(1):206. Published 2018 May 3.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:40.901+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e015a34b-7bcc-41cc-b0e3-157adc929535", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.68, "x": 0.28, "y": 0.08 }, "kind": "list", "text": "NTM is a group of >200 species of mycobacteria commonly found in water and soil; unlike tuberculosis, not transmitted person-to-person\nEpetaborole is being developed for the most common type of NTM, Mycobacterium avium complex (MAC)\nMAC causes ~80% of cases of NTM lung disease\nSymptoms similar to those associated with other chronic respiratory diseases\nCauses chronic infection that progresses to fibrosis, permanent lung damage and respiratory failure\nWomen and 65+ age group most affected\n5-year mortality rate between 10-48%", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:40.901+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ead048a9-9533-49f2-9b15-4b8529c153da", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.22, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "NTM lung disease a rare, chronic and progressive infectious disease", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:40.901+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e07975e6-76b1-4d77-98cf-a91a8648ee75", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Problem", "beatId": "3c9832b8-bfc2-4ca8-ad8d-8f1231fddb47", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slides 8-10 present the problem statement, market sizing, and current treatment regimens", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 10, "from": 8, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "13b74b4b-a68a-4f96-aedb-d9fa2b458a5f", "evidence": "The problem statement and market sizing slides imply the cost of inaction", "position": 0, "objective": "What is the cost of not addressing NTM lung disease?", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:24:39.618722+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 9, "type": "resolution", "title": "Uses a nested Venn/funnel diagram to illustrate market segmentation.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 76, "componentCount": 8, "textChars": 479, "nDataPoints": 4, "notes": "Uses a nested Venn/funnel diagram to illustrate market segmentation.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:47.48+00", "seconds": 9.231, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/9", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-9", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.8, "w": 0.35, "x": 0.65, "y": 0.15 }, "kind": "diagram", "text": "Nested circles representing market segments", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Venn diagram", "slug": "venn", "status": "active", "canonId": "019de52d-0463-710d-b529-cce18d828d2f", "version": 1, "description": null }, "framework": null }, "subkind": "venn", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:47.48+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "532e8535-6837-4847-b404-080c71d1acf7", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.35, "x": 0.29, "y": 0.38 }, "kind": "list", "text": "~44,000 Diagnosed with MAC lung disease", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:47.48+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1ab7c648-f12d-48c2-b7b7-f6ccecb372cd", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.35, "x": 0.29, "y": 0.21 }, "kind": "list", "text": "~55,000 Diagnosed with NTM lung disease", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:47.48+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3b52dd91-aff0-4fa0-8d59-27dcbf4dde10", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.35, "x": 0.29, "y": 0.56 }, "kind": "list", "text": "~15,000 Diagnosed with treatment-refractory MAC lung disease", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:47.48+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "64587c87-8690-4a75-ac2f-66bc695a9411", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.65, "x": 0.29, "y": 0.07 }, "kind": "metric", "text": "~200,000 estimated patients with NTM lung disease in U.S.", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:47.48+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b1e67e92-192e-4325-8765-e46047b4f8b2", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.22, "x": 0.05, "y": 0.31 }, "kind": "paragraph", "text": "Initial indication targeting treatment-refractory MAC lung disease", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:47.48+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "80684cdc-0797-4466-b8ef-03e811dc005d", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.35, "x": 0.29, "y": 0.67 }, "kind": "source-note", "text": "Treatment-refractory = Patients that remain culture positive despite ≥6 months of guideline-based antibiotic therapy", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:47.48+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "afa8038e-022b-477e-a5b0-303838bc9eb5", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.22, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "NTM lung disease underserved and growing market opportunity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:47.48+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "517ee7db-6756-4a73-9b10-f3a16a50bc65", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "d8eb4d09-a740-4a36-a7f4-0b1b0a2916f8", "evidence": "Nested circles showing total addressable market down to specific indication", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:36:47.48+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "market-segmentation-pyramid" } ], "arcBeats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Problem", "beatId": "3c9832b8-bfc2-4ca8-ad8d-8f1231fddb47", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slides 8-10 present the problem statement, market sizing, and current treatment regimens", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 10, "from": 8, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "13b74b4b-a68a-4f96-aedb-d9fa2b458a5f", "evidence": "The problem statement and market sizing slides imply the cost of inaction", "position": 0, "objective": "What is the cost of not addressing NTM lung disease?", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:24:39.618722+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "tension", "title": "The slide uses a two-part table structure to contrast standard care with refractory care, emphasizing toxicity and lack of FDA approval for many agents.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "balanced", "densityScore": 49, "componentCount": 5, "textChars": 305, "nDataPoints": 4, "notes": "The slide uses a two-part table structure to contrast standard care with refractory care, emphasizing toxicity and lack of FDA approval for many agents.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:41.152+00", "seconds": 2.758, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/10", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-10", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.045, "w": 0.39, "x": 0.435, "y": 0.408 }, "kind": "callout", "text": "If NTM culture positive after 6 months of treatment", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.152+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8e6b7746-7cf2-45af-bcd1-c9a7fc78cb56", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.24, "x": 0.03, "y": 0.51 }, "kind": "paragraph", "text": "All NTM treatments, except Arikayce, are used off-label", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.152+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "da3888a3-6b64-4859-972c-f06c6fd12bbc", "parentComponentId": null }, { "bbox": { "h": 0.375, "w": 0.678, "x": 0.291, "y": 0.065 }, "kind": "table", "text": "Treatment-Naïve Patients table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.152+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "91ca6954-3e3a-4957-afb7-0b3d05c1c7bd", "parentComponentId": null }, { "bbox": { "h": 0.405, "w": 0.678, "x": 0.291, "y": 0.49 }, "kind": "table", "text": "Treatment-Refractory Patients table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.152+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f52d5c04-e882-484e-937e-c9d787ba7e4c", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.24, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "Current treatment regimens for patients with NTM Mycobacterium avium complex (MAC) lung disease leave a significant unmet medical need", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.152+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "74c3bbd8-4035-404c-846c-f3315cd7d865", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "d82710ae-0a8a-4394-a8e6-11314dfdc777", "evidence": "The slide presents a problem statement with several components, including a headline, paragraph, callout, and tables.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:35:26.656737+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Problem", "beatId": "3c9832b8-bfc2-4ca8-ad8d-8f1231fddb47", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slides 8-10 present the problem statement, market sizing, and current treatment regimens", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 10, "from": 8, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "13b74b4b-a68a-4f96-aedb-d9fa2b458a5f", "evidence": "The problem statement and market sizing slides imply the cost of inaction", "position": 0, "objective": "What is the cost of not addressing NTM lung disease?", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:24:39.618722+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "setup", "title": "The slide presents a balanced view, showing both efficacy and significant safety/tolerability concerns for the competitor drug.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "dense", "densityScore": 56, "componentCount": 4, "textChars": 670, "nDataPoints": 6, "notes": "The slide presents a balanced view, showing both efficacy and significant safety/tolerability concerns for the competitor drug.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:41.556+00", "seconds": 3.017, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/11", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-11", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.68, "x": 0.29, "y": 0.54 }, "kind": "callout", "text": "Arikayce Boxed Warnings: Associated with an increased risk of respiratory conditions... Other common side effects: dysphonia, cough, ototoxicity, upper airway irritation, musculoskeletal pain, fatigue, diarrhea and nausea", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.556+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bad7036e-8d17-4cf3-a7e0-92936202daa7", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.25, "x": 0.02, "y": 0.07 }, "kind": "paragraph", "text": "Arikayce (Inhaled liposomal amikacin): first and only FDA-approved NTM lung disease drug. Arikayce is associated with a high discontinuation rate and increased adverse events versus SoC therapy alone", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.556+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6da19e88-246b-47de-85c0-bce2fe3a5175", "parentComponentId": null }, { "bbox": { "h": 0.38, "w": 0.68, "x": 0.29, "y": 0.14 }, "kind": "table", "text": "CONVERT Study Parameter | Arikayce | Control. Efficacy: Culture-converted by month 6 (29% vs 9%). Safety: Withdrawn from study (20% vs 9%), Upper respiratory adverse events (18% vs 2%), Ototoxicity (17% vs 10%)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.556+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3b2c51bd-1b0b-4b2a-935b-d36acf4b7bcb", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.4, "x": 0.29, "y": 0.06 }, "kind": "title", "text": "Arikayce Pivotal Study (CONVERT) Results", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.556+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7fb603a2-2a4e-413d-9af3-a7b9cb4b24df", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "d2e3fb02-9b5a-4ffa-8f98-5e1a321198b3", "evidence": "The slide presents a table with data from the CONVERT study.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 03:35:26.740035+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 12, "type": "resolution", "title": "Scientific illustration showing molecular binding interaction.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 32, "componentCount": 4, "textChars": 283, "nDataPoints": 0, "notes": "Scientific illustration showing molecular binding interaction.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:41.076+00", "seconds": 2.489, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/12", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-12", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.8, "w": 0.6, "x": 0.35, "y": 0.1 }, "kind": "image", "text": "Molecular structure diagram showing LeuRS, tRNALeu, and EBO binding site", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.076+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b8461245-671f-47f8-9bf2-7e339ca9441c", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.2, "x": 0.05, "y": 0.2 }, "kind": "paragraph", "text": "EBO inhibits the protein synthesis enzyme leucyl-tRNA synthetase (LeuRS) by binding to the terminal adenosine ribose of tRNALeu in the editing site", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.076+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "939d3b46-e994-40ea-8de0-4a7ad9337069", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.15, "x": 0.28, "y": 0.95 }, "kind": "source-note", "text": "V. Hernandez et al. AAC (2013) 57: 1394", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.076+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "10887e6a-35a9-4d41-8296-edb53771fe07", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.2, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Novel mechanism of action", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:41.076+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6d176eac-b912-400d-a4be-c3a506b5c7e7", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Solution", "beatId": "fbdd29f4-3b4e-4837-b922-52ede9c2a8ae", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 12-14 present the solution overview, including epetraborole's novel mechanism of action and broad antimicrobial activity", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 14, "from": 12, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "88233dcc-135b-430e-bef3-14bb541736d0", "evidence": "The solution overview slides present the why, what, and how of epetraborole", "position": 1, "objective": "Why is epetraborole a compelling solution?", "confidence": 0.8, "extraction": { "at": "2026-07-17 03:24:39.654225+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "setup", "title": "EBO = Epetraborole; MAC = Mycobacterium avium complex; MIC = Minimum Inhibitory Concentration.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 83, "componentCount": 7, "textChars": 960, "nDataPoints": 9, "notes": "EBO = Epetraborole; MAC = Mycobacterium avium complex; MIC = Minimum Inhibitory Concentration.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:42.071+00", "seconds": 3.224, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/13", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-13", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.68, "x": 0.29, "y": 0.75 }, "kind": "callout", "text": "EBO's novel MoA allows it to maintain activity against MAC isolates resistant to clarithromycin", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.071+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8fc88af0-694a-47af-bbc0-a7104a26f5ba", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.68, "x": 0.29, "y": 0.38 }, "kind": "list", "text": "Antimicrobial activity of epetraborole, clarithromycin and amikacin against 51 isolates of MAC including 17 M. intracellulare isolates, 1 M. avium isolates, 3 M. avium complex isolates, 20 M. avium subsp. hominissuis isolates, and 10 M. chimaera isolates", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.071+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "76e7dd56-3fbb-4b1c-b06e-3766b45c7815", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.68, "x": 0.29, "y": 0.55 }, "kind": "list", "text": "Clarithromycin is a generic macrolide antimicrobial used to treat patients with MAC lung disease and Arikayce is the only currently approved therapy for the treatment of MAC lung disease", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.071+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ad282000-0da3-45b3-93fd-42b48dbbbc8d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.05, "y": 0.21 }, "kind": "paragraph", "text": "EBO in vitro antimicrobial activity against 51 clinical isolates of MAC, with MICs between 0.25 µg/ml to 8 µg/ml", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.071+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "edb71661-7fbc-4c61-804a-92fa377da0a5", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.68, "x": 0.29, "y": 0.9 }, "kind": "source-note", "text": "Unpublished Data from Michelle S. DeStefano and Michael H. Cynamon, Central New York Research Corporation Syracuse, NY, United States * Amikacin is the active component of Arikayce", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.071+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7af4d48e-f3f9-47cf-b1a6-0d37ac19aa96", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.65, "x": 0.3, "y": 0.08 }, "kind": "table", "text": "MIC (mg/L) table comparing Epetraborole, Clarithromycin, and Amikacin across MIC Range, MIC50, and MIC90.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.071+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2bd83747-f9de-4656-b788-432c8306bc3a", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.05, "y": 0.07 }, "kind": "title", "text": "Broad antimicrobial activity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.071+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "42c982bc-5cc9-4162-af96-2c6ce94a41ff", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "660fd7c9-fcd1-4f18-9657-0dbd4575d7ab", "evidence": "The slide presents a table comparing MIC values for Epetraborole, Clarithromycin, and Amikacin.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 03:35:26.861773+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Solution", "beatId": "fbdd29f4-3b4e-4837-b922-52ede9c2a8ae", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 12-14 present the solution overview, including epetraborole's novel mechanism of action and broad antimicrobial activity", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 14, "from": 12, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "88233dcc-135b-430e-bef3-14bb541736d0", "evidence": "The solution overview slides present the why, what, and how of epetraborole", "position": 1, "objective": "Why is epetraborole a compelling solution?", "confidence": 0.8, "extraction": { "at": "2026-07-17 03:24:39.654225+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 14, "type": "evidence", "title": "The chart demonstrates dose-dependent efficacy of Epetraborole (EBO) against M. avium 2285 (R).", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 5, "textChars": 469, "nDataPoints": 9, "notes": "The chart demonstrates dose-dependent efficacy of Epetraborole (EBO) against M. avium 2285 (R).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:42.113+00", "seconds": 3.033, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/14", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-14", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.65, "x": 0.3, "y": 0.05 }, "kind": "chart", "text": "Epetraborole (EBO) and Clarithromycin (CLR) antibacterial activity in a chronic model of MAC lung disease in mice against M. avium 2285 (R)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "43302472-bd5d-4782-9f61-d4002e47ee36", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.05, "y": 0.85 }, "kind": "disclaimer", "text": "CFU = Colony Forming Units; EBO=Epetraborole; CLR=Clarithromycin", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "041cd0f2-9edc-46a5-a364-4f701825be30", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.05, "y": 0.35 }, "kind": "paragraph", "text": "Showed improved antibacterial activity of epetraborole at all doses compared to the daily humanized clarithromycin dose of 250 mg/kg", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "25856187-c551-49fc-8e58-d5f988bce94e", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.28, "y": 0.95 }, "kind": "source-note", "text": "Unpublished Data, Ordway Lab, CSU & AN2 Therapeutics", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f924e448-9903-4ef5-8748-8f0659fd76b5", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.25, "x": 0.05, "y": 0.07 }, "kind": "title", "text": "Epetraborole antibacterial activity in a chronic model of MAC lung disease in mice", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b2056ae6-4f63-4d36-8a15-7c6ea7583a6b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Solution", "beatId": "fbdd29f4-3b4e-4837-b922-52ede9c2a8ae", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 12-14 present the solution overview, including epetraborole's novel mechanism of action and broad antimicrobial activity", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.9 }, { "to": 17, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 14, "name": "Traction", "beatId": "679127e2-5c80-423c-8aa7-8057beadd113", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": null, "evidence": "Slides 14-17 present traction, including Epetraborole's improved antibacterial activity and favorable pharmacokinetics", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 14, "from": 12, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "88233dcc-135b-430e-bef3-14bb541736d0", "evidence": "The solution overview slides present the why, what, and how of epetraborole", "position": 1, "objective": "Why is epetraborole a compelling solution?", "confidence": 0.8, "extraction": { "at": "2026-07-17 03:24:39.654225+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 15, "type": "evidence", "title": "The charts demonstrate dose-dependent efficacy and synergy between EBO and SoC.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 8, "textChars": 446, "nDataPoints": 24, "notes": "The charts demonstrate dose-dependent efficacy and synergy between EBO and SoC.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:42.136+00", "seconds": 2.999, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/15", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-15", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.3, "x": 0.65, "y": 0.5 }, "kind": "chart", "text": "D. M. intracellulare DNA00055", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.136+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "21e0a232-4175-4087-b561-ce7877f0712e", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.3, "x": 0.32, "y": 0.5 }, "kind": "chart", "text": "C. M. intracellulare DNA00111", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.136+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "33bd8d97-3c14-440a-9ae1-1ae8e0e126e0", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.3, "x": 0.65, "y": 0.05 }, "kind": "chart", "text": "B. M. intracellulare 1956", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.136+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ac63962b-fb90-48a9-84ea-b1f0d9aab673", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.3, "x": 0.32, "y": 0.05 }, "kind": "chart", "text": "A. M. avium ATCC 700898", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.136+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b1fffa84-5d60-4db6-8476-ab00cc71c357", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.23, "x": 0.03, "y": 0.82 }, "kind": "disclaimer", "text": "CFU = Colony Forming Units; EBO=epetraborole; SOC=clarithromycin, ethambutol, rifabutin", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.136+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f9a73fe1-2be4-43e5-8d01-2770e9823175", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.23, "x": 0.03, "y": 0.35 }, "kind": "paragraph", "text": "Significant reductions in MAC CFU with EBO monotherapy; superior decreases with EBO + SoC regimen compared to SoC alone", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.136+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "773a6dc2-bb51-4d04-b24b-7f3f6f8e766c", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.28, "y": 0.96 }, "kind": "source-note", "text": "Unpublished Data, Ordway Lab, CSU & AN2 Therapeutics", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.136+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "93910ece-5f38-4ca7-92ac-923412c86412", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.23, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "Epetraborole antibacterial activity in a chronic model of MAC lung disease in mice", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.136+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "82d88d97-0fba-4745-8f5a-d368413db393", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 17, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 14, "name": "Traction", "beatId": "679127e2-5c80-423c-8aa7-8057beadd113", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": null, "evidence": "Slides 14-17 present traction, including Epetraborole's improved antibacterial activity and favorable pharmacokinetics", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [], "locked": true }, { "page": 16, "type": "evidence", "title": "Includes a timeline diagram of the study design and bulleted clinical outcomes.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 80, "componentCount": 7, "textChars": 808, "nDataPoints": 5, "notes": "Includes a timeline diagram of the study design and bulleted clinical outcomes.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:42.76+00", "seconds": 3.486, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/16", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-16", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.69, "x": 0.273, "y": 0.815 }, "kind": "callout", "text": "500 mg once-daily dose achieved exposures suggesting high probability of PK/PD target attainment for treatment of MAC lung disease and was well-tolerated", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.76+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6ce57df8-1fff-40ce-b3af-43c8c9659d4d", "parentComponentId": null }, { "bbox": { "h": 0.315, "w": 0.665, "x": 0.301, "y": 0.108 }, "kind": "diagram", "text": "Study design timeline showing Day 1, Treatment Period, EOT, and LFU", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.76+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9b55fb0e-c8db-44f7-ab92-22608899dfa3", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.66, "x": 0.301, "y": 0.665 }, "kind": "list", "text": "Data from EBO-101 and 6 other clinical studies combined into Population PK model; EBO-101 results used in combination with preclinical data to determine epetraborole oral dosage for Study EBO-301 Phase 2/3 pivotal trial", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.76+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3a816733-2957-43e9-a212-ee4f92a847cb", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.55, "x": 0.301, "y": 0.458 }, "kind": "list", "text": "Epetraborole generally well-tolerated; No serious adverse events (SAEs), no severe AEs, no deaths; Linear PK", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.76+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4a890c4b-69dc-48e2-9e02-8ea36c1f2a6f", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.69, "x": 0.273, "y": 0.625 }, "kind": "paragraph", "text": "Results support further clinical development of epetraborole in NTM lung disease", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.76+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b235980d-c76b-40ec-b3b9-805da7d62040", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.24, "x": 0.02, "y": 0.07 }, "kind": "title", "text": "EBO-101: A 28-Day Phase 1b dose-ranging study of oral epetraborole supports 500 mg once-daily dose for patients with treatment-refractory MAC lung disease", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.76+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "09adaa91-7eaf-44f5-b037-65ce0c29a300", "parentComponentId": null }, { "bbox": { "h": 0.032, "w": 0.265, "x": 0.298, "y": 0.058 }, "kind": "title", "text": "Phase 1b Design and Results", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.76+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c97ca0fb-3197-439b-b224-5a30e0688168", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 17, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 14, "name": "Traction", "beatId": "679127e2-5c80-423c-8aa7-8057beadd113", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": null, "evidence": "Slides 14-17 present traction, including Epetraborole's improved antibacterial activity and favorable pharmacokinetics", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [], "locked": true }, { "page": 17, "type": "evidence", "title": "The slide highlights the therapeutic potential of the drug by showing superior accumulation at the site of infection.", "function": "analyze_data", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 64, "componentCount": 6, "textChars": 476, "nDataPoints": 2, "notes": "The slide highlights the therapeutic potential of the drug by showing superior accumulation at the site of infection.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:43.297+00", "seconds": 4.018, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/17", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-17", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.2, "x": 0.45, "y": 0.3 }, "kind": "callout", "text": "4.98x more drug in AM than in plasma", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.297+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "50c9b3cb-512c-4b87-8b48-429fc0651c05", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.35, "x": 0.35, "y": 0.1 }, "kind": "chart", "text": "Composite AUC(0-t) (ng•h/mL) for Plasma vs AM", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.297+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cf88fa0c-a285-4cb3-a928-56b5bef3a084", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.65, "x": 0.3, "y": 0.75 }, "kind": "paragraph", "text": "Results suggest therapeutically relevant doses of epetraborole may be achieved in macrophages at doses that are substantially lower than MTD in previous trials", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.297+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9398a13c-7316-49d6-a769-4bb6b21f02f6", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.05, "y": 0.22 }, "kind": "paragraph", "text": "Results from Phase 1 trial showed the concentration in lung macrophages (site of NTM infection) was 5x higher than in plasma", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.297+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d36d94f3-4b32-4ee1-9fe6-f67356914067", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.4, "y": 0.65 }, "kind": "source-note", "text": "1AUC based on concentrations at 2,6, and 12-hour timepoints. AM = alveolar macrophages", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.297+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e0e66058-4d37-4fef-af12-475e791b0521", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.05, "y": 0.07 }, "kind": "title", "text": "Favorable pharmacokinetics", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.297+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4a510282-7188-413a-9e60-5a08f392bd5a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 17, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 14, "name": "Traction", "beatId": "679127e2-5c80-423c-8aa7-8057beadd113", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": null, "evidence": "Slides 14-17 present traction, including Epetraborole's improved antibacterial activity and favorable pharmacokinetics", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [], "locked": true }, { "page": 18, "type": "resolution", "title": "The slide outlines a seamless transition between Phase 2 and Phase 3 trials for a specific drug candidate.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 64, "componentCount": 5, "textChars": 708, "nDataPoints": 4, "notes": "The slide outlines a seamless transition between Phase 2 and Phase 3 trials for a specific drug candidate.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:42.878+00", "seconds": 3.486, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/18", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-18", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.85, "w": 0.68, "x": 0.28, "y": 0.01 }, "kind": "diagram", "text": "Phase 2 and Phase 3 trial design timelines", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.878+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "22a22f8b-98d6-4d2d-acd5-2d7673d2c2d2", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.24, "x": 0.03, "y": 0.4 }, "kind": "paragraph", "text": "Plan to use LPAD pathway in U.S. Microbiological primary endpoint in Japan to support potential registration", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.878+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6870de3f-0cd5-4f4d-9ae9-24f4a2bf91a7", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.5, "x": 0.28, "y": 0.89 }, "kind": "source-note", "text": "* Patients who culture convert will be treated for 12 months from 1st negative culture per treatment guidelines. EOT = End-of-Therapy; LFU = Late Follow-up; LPAD = Limited population anti-infective drug pathway; OBR = Optimized Background Regimen; TBD = Final sample size to be confirmed based on Phase 2 Part data; Timelines are approx, reflect current forecast, and are subject to change.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.878+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "58bb8e14-6e7a-4e46-85f0-cc43f6fa57dc", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.2, "x": 0.78, "y": 0.82 }, "kind": "table", "text": "Milestones: Mid '23 – Ph 2 topline data; Mid '24 – Ph 3 topline data", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.878+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "87c6aaef-5ecf-4f85-9825-40bf11e26036", "parentComponentId": null }, { "bbox": { "h": 0.32, "w": 0.24, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "EBO-301: A Phase 2/3 pivotal clinical trial of epetraborole in treatment-refractory MAC lung disease", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.878+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "62b13480-4d56-4f8f-8d08-226f4155812c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "058d9001-c49a-429b-9ebd-9a83bf29971b", "evidence": "Visual representation of clinical trial phases over time", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:36:42.878+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 19, "type": "resolution", "title": "Uses a funnel-like diagram to represent market segments.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 78, "componentCount": 7, "textChars": 631, "nDataPoints": 9, "notes": "Uses a funnel-like diagram to represent market segments.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:43.043+00", "seconds": 3.617, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/19", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-19", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.45, "x": 0.5, "y": 0.55 }, "kind": "chart", "text": "United States, Europe, Japan patient data", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": null, "framework": null }, "subkind": "map", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ca54d4ff-3e71-48d4-bb09-f4c6fc8d0eac", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.15, "x": 0.26, "y": 0.05 }, "kind": "diagram", "text": null, "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": "funnel", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0527da15-08eb-4d1a-a424-8f349bc65c6d", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.5, "x": 0.45, "y": 0.05 }, "kind": "list", "text": "US Treatment-Refractory (TR) NTM Lung Disease caused by MAC\nGlobal TR NTM Lung Disease caused by MAC\nUS Treatment-Naïve (TN) NTM Lung Disease caused by MAC\nGlobal TN NTM Lung Disease caused by MAC\nM. abscessus & Cystic Fibrosis NTM Lung Disease", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "19e84fea-19e6-4684-b424-e806386e2705", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.05, "y": 0.26 }, "kind": "paragraph", "text": "Significant growth opportunity in ex-US markets with additional labeled indications", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9ac22120-5ba8-4dd0-8565-fb55f1de47ed", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.22, "x": 0.27, "y": 0.55 }, "kind": "paragraph", "text": "ARIKAYCE® reported WW net sales of over $189M in 2021... Prevalence estimated to increase by ~8% per year in the U.S.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bcdfef1e-c3c7-4467-8e10-5789f1245a4a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.27, "y": 0.92 }, "kind": "source-note", "text": "1. Insmed FY 2021 10-K... 5. Strollo SE, et al. Ann Am Thorac Soc. 2015;12(10):1458-1464", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0a38b61d-d23b-47d8-9c46-607d96dee258", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "Commercial strategy: establish treatment refractory market", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a227006d-90a3-4a65-8a77-37eb5f23cf9f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "63440f13-d587-4e09-bcad-117c2b654150", "evidence": "Funnel diagram used to segment NTM lung disease markets", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:36:43.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "frameworkName": "market-segmentation-pyramid" } ], "arcBeats": [ { "to": 22, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 19, "name": "Business Model", "beatId": "397f2f22-31e1-4ec6-8a66-a5d5f79bbcd3", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": { "name": "Business Model", "slug": "sequoia-pitch-business-model", "status": "active", "canonId": "019dd9b8-22f4-768a-8822-31509f575122", "version": 1, "description": null }, "evidence": "Slides 19-22 present the business model, including market opportunity, target product profile, and intellectual property", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [], "locked": true }, { "page": 20, "type": "setup", "title": "The table uses checkmarks and X marks to denote performance against specific clinical criteria.", "function": "compare_peers", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 4, "textChars": 554, "nDataPoints": 28, "notes": "The table uses checkmarks and X marks to denote performance against specific clinical criteria.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:42.647+00", "seconds": 2.588, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/20", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-20", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.68, "x": 0.28, "y": 0.88 }, "kind": "disclaimer", "text": "TPP criteria and product profiles presented in this table are based on an in-house analysis of published data, drug product labeling, and have been combined from multiple sources presented in different studies.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.647+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8df34156-9b9c-4a03-a492-34a6cb9c9d60", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.68, "x": 0.28, "y": 0.82 }, "kind": "source-note", "text": "1. Wu ML, Aziz DB, Dartois V, Dick T. NTM drug discovery: status, gaps and the way forward. Drug Discov Today. 2018;23(8):1502-1519. 2. Spero Therapeutics. 3. Redhill Biopharma.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.647+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "766ddf59-ef29-4cd9-91b3-1f9895362a95", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.68, "x": 0.28, "y": 0.08 }, "kind": "table", "text": "Planned Target Product Profile (TPP) Criteria", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.647+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "89072a09-6dfe-4ef7-95a6-56f32460321e", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.25, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "Attractive target product profile to address unmet needs in NTM with potential to become an important component of therapy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.647+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4a559dc6-557d-43e2-8491-b6a1b6996023", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Comparison frame", "slug": "comparison-frame", "status": "active", "bestFor": null, "canonId": "019dd9e1-484b-7399-a4fc-d14644b99f93", "version": 1, "bodyDocId": null, "description": "Two or more states/subjects placed side by side to expose a gap.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3b646261-1d64-442f-b3bc-cce41a534d4a", "evidence": "comparison_table", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:35:43.494542+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "b014cb5c-bd4a-4cbf-9c8e-a09154bd086d", "evidence": "Comparison of product features against competitors", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:36:42.647+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "frameworkName": "comparison_frame" } ], "arcBeats": [ { "to": 22, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 19, "name": "Business Model", "beatId": "397f2f22-31e1-4ec6-8a66-a5d5f79bbcd3", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": { "name": "Business Model", "slug": "sequoia-pitch-business-model", "status": "active", "canonId": "019dd9b8-22f4-768a-8822-31509f575122", "version": 1, "description": null }, "evidence": "Slides 19-22 present the business model, including market opportunity, target product profile, and intellectual property", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [], "locked": true }, { "page": 21, "type": "setup", "title": "QIDP = Qualified Infectious Disease Product Designation", "function": "other", "rawType": "unfair_advantage", "block": null, "metadata": { "slideType": "unfair_advantage", "slideTypeCanon": { "name": "Unfair advantage", "slug": "unfair_advantage", "status": "active", "canonId": "019de52d-0f56-744f-8bb4-c8a8cca240d6", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "dense", "densityScore": 70, "componentCount": 7, "textChars": 431, "nDataPoints": 6, "notes": "QIDP = Qualified Infectious Disease Product Designation", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:43.703+00", "seconds": 3.54, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/21", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-21", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.75, "x": 0.25, "y": 0.1 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Map", "slug": "map", "status": "active", "canonId": "019de52c-fe4d-77bd-b0a4-d72d58b9e5a4", "version": 1, "description": null }, "framework": null }, "subkind": "map", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.703+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b766e3ae-b141-4a6e-8f0e-f8b9456a60aa", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.28, "y": 0.65 }, "kind": "list", "text": "U.S. Regulatory Exclusivity: Up to 12 years post-marketing (Orphan Drug 7 years, Gain Act 5 years)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.703+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1e363c4f-7964-4efc-b6bc-ff037330a685", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.6, "y": 0.65 }, "kind": "list", "text": "Europe provides 10 years of exclusivity from launch with centralized filing", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.703+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5663b3af-2bf3-4e72-aaa2-dd7d84ea445a", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.15, "x": 0.78, "y": 0.65 }, "kind": "list", "text": "Similar mechanisms available in Japan", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.703+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a658b4cc-ed9f-4335-94bc-b1408d6dbb5c", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.25, "x": 0.28, "y": 0.25 }, "kind": "list", "text": "Composition of Matter (COM) patent expires June 2028; Up to 4-5 years of extensions; Protection up to ~June 2033", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.703+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ecc2fc55-e98f-4ab1-8173-747531456da3", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.28, "y": 0.9 }, "kind": "source-note", "text": "QIDP = Qualified Infectious Disease Product Designation", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.703+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8cdbb191-eb4f-46e8-b012-40cd95ee7585", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Intellectual property: ≥ Up to 12 years of exclusivity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:43.703+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eea83695-724f-4284-96ff-aa8700ea5e95", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "69c3b563-3b32-41b3-8645-5818d9ea391d", "evidence": "source-note: 1. Wu ML, Aziz DB, Dartois V, Dick T. NTM drug discovery: status, gaps and the way forward. Drug Discov Today. 2018;23(8):1502-1519. 2. Spero Therapeutics. 3. Redhill Biopharma.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 03:35:43.576205+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 22, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 19, "name": "Business Model", "beatId": "397f2f22-31e1-4ec6-8a66-a5d5f79bbcd3", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": { "name": "Business Model", "slug": "sequoia-pitch-business-model", "status": "active", "canonId": "019dd9b8-22f4-768a-8822-31509f575122", "version": 1, "description": null }, "evidence": "Slides 19-22 present the business model, including market opportunity, target product profile, and intellectual property", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [], "locked": true }, { "page": 22, "type": "resolution", "title": "The timeline shows clinical trial phases (Chronic Tox, Phase 1b, Ph 2/3 TR-MAC, Ph 1 Japan, Ph 2/3 Topline Data).", "function": "plan_implementation", "rawType": "use_of_funds", "block": null, "metadata": { "slideType": "use_of_funds", "slideTypeCanon": { "name": "Use of funds", "slug": "use_of_funds", "status": "active", "canonId": "019de52d-1045-737c-90e9-c79600f9e2c7", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 25, "componentCount": 3, "textChars": 214, "nDataPoints": 1, "notes": "The timeline shows clinical trial phases (Chronic Tox, Phase 1b, Ph 2/3 TR-MAC, Ph 1 Japan, Ph 2/3 Topline Data).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:42.889+00", "seconds": 2.539, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/22", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-22", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.18, "w": 0.68, "x": 0.28, "y": 0.4 }, "kind": "chart", "text": "Clinical trial timeline from 2021 to 2024", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": null, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.889+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bf0e9b89-1928-4efc-a8c8-f4b7d432169c", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.6, "x": 0.28, "y": 0.11 }, "kind": "list", "text": "$115.8 cash, cash equivalents and investments as of 6/30/2022\nExpect to be sufficient to fund operating expenses through mid-2024", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.889+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "176bbdaa-b813-4f5a-9d5c-bbeea49289a2", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.24, "x": 0.02, "y": 0.07 }, "kind": "title", "text": "Existing cash funds value driving milestones", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:42.889+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4eaa4576-587f-4c96-b0d8-a55760dd69be", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4a060af3-898d-49bc-b20a-cd2a3c7d43ae", "evidence": "chart/timeline: Clinical trial timeline from 2021 to 2024", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:07:28.729471+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "748ed387-ce5e-41d3-a4e9-9c1818b61eb8", "evidence": "The slide uses a horizontal timeline to map clinical milestones against calendar years.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:36:42.889+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "frameworkName": "timeline" } ], "arcBeats": [ { "to": 22, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 19, "name": "Business Model", "beatId": "397f2f22-31e1-4ec6-8a66-a5d5f79bbcd3", "matchId": "cbbf4562-c23a-466b-8662-c050573c01cd", "beatType": { "name": "Business Model", "slug": "sequoia-pitch-business-model", "status": "active", "canonId": "019dd9b8-22f4-768a-8822-31509f575122", "version": 1, "description": null }, "evidence": "Slides 19-22 present the business model, including market opportunity, target product profile, and intellectual property", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [], "locked": true }, { "page": 23, "type": "setup", "function": "inspire_vision", "rawType": "mission", "block": null, "metadata": { "slideType": "mission", "slideTypeCanon": { "name": "Mission", "slug": "mission", "status": "active", "canonId": "019de52d-0fce-7496-b34c-18fd6a6e3310", "version": 1, "description": null }, "function": "inspire_vision", "functionCanon": { "name": "Inspire vision", "slug": "inspire_vision", "status": "active", "canonId": "019de52d-16d0-7756-83de-376eeac6fa40", "version": 1, "description": null }, "density": "balanced", "densityScore": 44, "componentCount": 5, "textChars": 348, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:49.516+00", "seconds": 9.115, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/23", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-23", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.2, "x": 0.03, "y": 0.065 }, "kind": "image", "text": "NIH, Adjuvant Capital", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:49.516+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "262a6530-7d7a-479b-bbc3-b88b18451a9e", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.62, "x": 0.33, "y": 0.055 }, "kind": "image", "text": "MORU, Colorado State University, NIH", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:49.516+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c350a0b3-9081-44a9-b842-dff70c2c4237", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.68, "x": 0.29, "y": 0.18 }, "kind": "list", "text": "AN2 leadership team is committed to applying our know-how to help solve some of the toughest infections in global health. Intent is to fund these efforts primarily through non-dilutive funding. The highest priority is melioidosis.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:49.516+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2c5eddb0-c591-4896-bf88-10d666e46bd1", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.2, "x": 0.03, "y": 0.056 }, "kind": "paragraph", "text": "Global health agreement partners:", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:49.516+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f5999c76-beb7-4759-96ee-d39c853881e6", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.22, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "Our global health commitment", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:49.516+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "44430eb2-03a4-428e-9145-04f405a15301", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "9cf297fa-c309-4359-8a06-98b9cfe387b1", "evidence": "list/bullet: AN2 leadership team is committed to applying our know-how to help solve some of the toughest infections in global health.", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:07:28.799885+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 24, "type": "setup", "title": "The slide uses a split-layout with a company mission statement on the left and product-specific details on the right.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 87, "componentCount": 8, "textChars": 1198, "nDataPoints": 4, "notes": "The slide uses a split-layout with a company mission statement on the left and product-specific details on the right.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 15:31:39.997+00", "seconds": 3.71, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/24", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-24", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.65, "x": 0.3, "y": 0.82 }, "kind": "callout", "text": "We expect our boron chemistry expertise to drive future pipeline of differentiated compounds", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:39.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e7a35c55-1143-4f01-9f24-8e88ca20f00d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.65, "x": 0.3, "y": 0.2 }, "kind": "list", "text": "Large market opportunity given the high unmet need; Arikayce, the only approved therapy for NTM lung disease, had 2021 WW net sales of >$189M in its third year on the market (Arikayce 2Q'22: WW $65.2M +44% Y/Y)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:39.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1a78cd20-6157-45af-8c17-95deaf5c0984", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.65, "x": 0.3, "y": 0.35 }, "kind": "list", "text": "Ideal Target Product Profile: Novel mechanism of action, broad spectrum antimycobacterial activity; Convenient, once-daily oral dosing; Superior profile compared to SoC combination regimen in preclinical NTM models; Multiple Phase 1 studies", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:39.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "49407ce5-5739-4b5f-aa1e-e4a64822814e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.65, "x": 0.3, "y": 0.75 }, "kind": "list", "text": "Potential to develop epetraborole to address additional geographies and NTM indications", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:39.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "77e05e4b-a865-48ad-97e7-e06b2dbb77d2", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.65, "x": 0.3, "y": 0.1 }, "kind": "list", "text": "Epetraborole (EBO): Pivotal phase 2/3 ready antibiotic product candidate for non-tuberculous mycobacterial (NTM) lung disease", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:39.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8449be1a-3e36-4226-82df-8006632788b0", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.65, "x": 0.3, "y": 0.6 }, "kind": "list", "text": "Phase 2/3 pivotal trial expected to support U.S. and Japan regulatory approval for treatment-refractory MAC lung disease; initiated study June 2022; topline Phase 2 data mid 2023; QIDP, Fast Track, and orphan drug designations granted in U.S.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:39.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ea1106f3-8dd1-4ffb-a0ee-aaf5d8edcb6f", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.25, "x": 0.05, "y": 0.15 }, "kind": "paragraph", "text": "AN2 Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:39.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "79a9893b-eeed-4ffc-82d0-71d8bfc28795", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.3, "y": 0.95 }, "kind": "source-note", "text": "1. Insmed FY 2021 10-K 2. Insmed 2Q 2022 10-Q", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:39.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "afe0401f-ff47-49c4-8b93-b5ec6140b770", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "ef02a5bb-4f19-4287-bf58-a35155d31fc6", "evidence": "list/bullet: Phase 2/3 pivotal trial expected to support U.S. and Japan regulatory approval for treatment-refractory MAC lung disease; initiated study June 2022; topline Phase 2 data mid 2023; QIDP, Fast Track, and orpha", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:07:28.869446+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 25, "type": "setup", "title": "The slide uses a global map background and patient portraits to emphasize the scope and human impact of the company's mission.", "function": "inspire_vision", "rawType": "mission", "block": null, "metadata": { "slideType": "mission", "slideTypeCanon": { "name": "Mission", "slug": "mission", "status": "active", "canonId": "019de52d-0fce-7496-b34c-18fd6a6e3310", "version": 1, "description": null }, "function": "inspire_vision", "functionCanon": { "name": "Inspire vision", "slug": "inspire_vision", "status": "active", "canonId": "019de52d-16d0-7756-83de-376eeac6fa40", "version": 1, "description": null }, "density": "balanced", "densityScore": 25, "componentCount": 4, "textChars": 154, "nDataPoints": 0, "notes": "The slide uses a global map background and patient portraits to emphasize the scope and human impact of the company's mission.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:36:44.538+00", "seconds": 4.114, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/25", "deck": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9", "deckAnchor": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-25", "deckJson": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json" }, "components": [ { "bbox": { "h": 0.85, "w": 0.55, "x": 0.4, "y": 0.08 }, "kind": "image", "text": "Group of patient portraits", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:44.538+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a3e09145-36c1-4c49-bf02-b0b6d23f61ef", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.38, "x": 0.03, "y": 0.32 }, "kind": "paragraph", "text": "Developing treatments for rare, chronic, and serious infectious diseases with high unmet needs", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:44.538+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "21d4c6ad-57f6-405e-9207-ed2262e18793", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.03, "y": 0.95 }, "kind": "paragraph", "text": "AN2THERAPEUTICS.COM", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:44.538+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5190fcc3-97ef-42e2-9784-ea464fbfdd94", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.35, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "AN2Therapeutics", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:36:44.538+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "70387533-2c48-4d49-89eb-839d890c109a", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Audience Persona", "slug": "audience-persona", "status": "active", "bestFor": null, "canonId": "019dd956-7fe3-74e9-88b8-be0bea34f219", "version": 1, "bodyDocId": null, "description": "Detailed fictional profile of typical audience member including goals, frustrations, and context", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "fbe0f7d1-5b65-40ef-b799-9678955ca8ad", "evidence": "paragraph/paragraph: Developing treatments for rare, chronic, and serious infectious diseases with high unmet needs", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:07:28.940039+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 8, "to": 10, "label": "Problem", "description": "Slides 8-10 present the problem statement, market sizing, and current treatment regimens" }, { "from": 12, "to": 14, "label": "Solution", "description": "Slides 12-14 present the solution overview, including epetraborole's novel mechanism of action and broad antimicrobial activity" }, { "from": 14, "to": 17, "label": "Traction", "description": "Slides 14-17 present traction, including Epetraborole's improved antibacterial activity and favorable pharmacokinetics" }, { "from": 19, "to": 22, "label": "Business Model", "description": "Slides 19-22 present the business model, including market opportunity, target product profile, and intellectual property" } ], "loops": [ { "from": 8, "to": 10, "label": "Cost Of Inaction", "description": "What is the cost of not addressing NTM lung disease?" }, { "from": 12, "to": 14, "label": "Golden Circle", "description": "Why is epetraborole a compelling solution?" } ] }